Kidney Cancer Weekly

October 06, 2025

Videos

Peer-to-Peer Clinical Conversations

Validation Study of the GRANT Score for Papillary Renal Cell Carcinoma - Michele Maffezzoli

Pedro Barata speaks with Michele Maffezzoli to discuss his validation of the GRANT score for papillary renal cell carcinoma.

Advancing the Management of Indeterminate Renal Masses: The Emerging Role of Molecular Imaging - Alexander Kutikov

Alexander Kutikov

Zachary Klaassen discusses indeterminate renal mass management with Alexander Kutikov.

Beyond the Abstracts

Immune-Based Combinations in Intermediate-/Poor-Risk Patients with Non-Clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study - Beyond the Abstract

Radiogenomic Correlation of Hypoxia-Related Biomarkers in Clear Cell Renal Cell Carcinoma - Beyond the Abstract

Conference Coverage

ASTRO 2025: Ultra-Hypofractionated Stereotactic Ablative Body Radiotherapy (SABR) for Primary Renal Cell Carcinoma: Pooled Outcomes from the FASTRACK and FASTRACK II Clinical Trials

ASTRO 2025: 265 - Long-Term Follow-up Results after Stereotactic Body Radiotherapy for Primary Renal Cell Carcinoma: A Prospective Multicenter Phase 2 Trial

ASTRO 2025: Stereotactic Radiation for Systemic Therapy-naïve Oligometastatic Kidney Cancer: Final Results of a Phase IIb Trial

ASTRO 2025: Discussant: Revelations in Renal Radiotherapy

ASTRO 2025: Neoadjuvant Pembrolizumab and Stereotactic Radiotherapy Prior to Nephrectomy for Renal Cell Carcinoma (NAPSTER): A Phase II Randomized Clinical Trial

Articles

Editor Selected Abstracts and Commentaries

Renal Cancer

Visfatin Promotes Renal Cell Carcinoma Progression: Evidence from Clinical Samples and Cell Line Models.

Effectiveness of Nivolumab-Based Immunotherapy and Prognostic Stratification by the Meet-URO Score in Real-World Older Patients with Metastatic Renal Cell Carcinoma - Beyond the Abstract

Machine learning-based analysis identifies glucose metabolism-related genes ADPGK as potential diagnostic biomarkers for clear cell renal cell carcinoma.

Impact of starting dose of tyrosine kinase inhibitors on outcomes following combination therapy of immune checkpoint inhibitors with tyrosine kinase inhibitors for previously untreated advanced renal cell carcinoma.

Identification of biomarkers for renal cell carcinoma in plasma samples measured using liquid chromatography-mass spectrometry and gas chromatography-mass spectrometry.

Biphasic (squamoid) papillary renal cell carcinoma: a distinct molecular and morphologic subtype within the PRCC spectrum.

Ablative techniques in renal tumours for inoperable patients: Step forward in SBRT.

Clinical Practice and Prognostic Molecular Biomarkers in Clear Cell Renal Cell Carcinoma: Latest Advancements.

Cancer-specific Mortality After Radical Nephrectomy and Thrombectomy for Renal Cell Carcinoma with Tumor Thrombus According to Histological Subtypes.

Small renal masses: Where do we stand? An updated analysis of trends and outcomes from the SEER database (2000-2021).

CDCA8 and TROAP as Prognostic Biomarkers of Postoperative Metastatic Progression in Clear Cell Renal Cell Carcinoma.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2025 Digital Science Press, LLC